Q4/2016 fiscal is over for Thera andQ4/2016 calendar is almost finished. Did you submit the final BLA, Luc? Catalysts Abound for ibalizumab, says Uddin. Egrifta continues to provide a solid revenue base for TH to build upon. We believe the reason for owning the stock is for the growth potential surrounding THs novel HIV treatment ibalizumab. We expect more ibalizumab data pertaining to safety and the primary endpoint at the ID Week in New Orleans on October 29, more clinical data pertaining to the secondary endpoints in November, a BLA filing for ibalizumab in Q4/2016 and U.S. commercialization in Q3/2017. Ibalizumab has FDA priority review designation which would shorten the BLA review time from 10 months to 6 months.